Mesoblast wins FDA assay approval: what it means for Mesoblast stock

Published on 10/07/2026 at 00:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

For Mesoblast stock, TIBA will monitor every new Ryoncil lot. Fiscal 2026 revenue reached USD 120.25 million, up 599.20 percent.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Mesoblast (ISIN AU000000MSB8) had a prior close of EUR 1.24 at Lang & Schwarz on October 5, 2026. On September 24, 2026, the company announced FDA approval for a new potency assay for commercial Ryoncil, as reported in its StockTitan filing summary.

FDA assay supports batch controls

The T-cell Proliferation Inhibition BioAssay, or TIBA, will be used for release and stability monitoring of every new commercial Ryoncil lot. The test will join existing assays for IL-2R alpha inhibition and cell adhesion and proliferation, creating a three-part batch-release matrix.

Ryoncil is approved for steroid-refractory acute graft-versus-host disease in patients aged 2 months or older. The September 24 filing says the assay is intended to detect potency shifts linked to manufacturing changes or production at new facilities.

Revenue reached USD 120.25 million

Mesoblast reported fiscal 2026 revenue of USD 120.25 million, compared with USD 17.20 million in fiscal 2025, a gain of 599.20 percent, according to Zacks. Fiscal 2026 gross profit was USD 103.58 million, versus USD 12.07 million a year earlier.

The GAAP net loss narrowed to USD 57.50 million in fiscal 2026 from USD 102.14 million in fiscal 2025, a 43.72 percent reduction. Cash and cash equivalents stood at USD 102.91 million on June 30, 2026, while operating cash flow was negative USD 43.83 million.

Nasdaq range remains wide

Mesoblast is listed on Nasdaq under MESO, with a USD 13.05 to USD 21.50 52-week range and a USD 1.8 billion market capitalization as of October 6, 2026. The latest finance quote showed USD 13.61, placing the price USD 7.89 below the 52-week high, or 36.70 percent below that level.

The operating picture has therefore changed quickly from development-stage economics to commercial revenue, while the fiscal 2026 loss and negative operating cash flow still mark the funding demands of the cell-therapy pipeline. The FDA assay approval addresses manufacturing control, but it does not itself add a new indication or expand Ryoncil's approved patient group.

Prior close sets the euro reference

At Lang & Schwarz, the prior close was EUR 1.24 on October 5, 2026. On Nasdaq, MESO was last at USD 13.61 on October 6, 2026 at 4:00 p.m. ET, separate from the euro reference price and its prior-close date. The further course of trading is shown by the continuously updated real-time quote of Mesoblast stock.